Clinical Trial Update: 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

View source ↗

Summary

A completed clinical trial investigating PET imaging with 89Zr-labeled bevacizumab to visualize neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Neuroendocrine Tumors | Status: COMPLETED